CN113924305A - Dna依赖性蛋白激酶抑制剂 - Google Patents

Dna依赖性蛋白激酶抑制剂 Download PDF

Info

Publication number
CN113924305A
CN113924305A CN202080039438.4A CN202080039438A CN113924305A CN 113924305 A CN113924305 A CN 113924305A CN 202080039438 A CN202080039438 A CN 202080039438A CN 113924305 A CN113924305 A CN 113924305A
Authority
CN
China
Prior art keywords
methyl
mmol
equiv
pyrazolo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080039438.4A
Other languages
English (en)
Chinese (zh)
Inventor
齐长河
徐汉忠
曾庆北
杨振帆
张小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizhe Jiangsu Pharmaceutical Co ltd
Dizhe Shanghai Pharmaceutical Co ltd
Original Assignee
Dizhe Jiangsu Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizhe Jiangsu Pharmaceutical Co ltd filed Critical Dizhe Jiangsu Pharmaceutical Co ltd
Publication of CN113924305A publication Critical patent/CN113924305A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080039438.4A 2019-05-27 2020-05-26 Dna依赖性蛋白激酶抑制剂 Pending CN113924305A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019088573 2019-05-27
CNPCT/CN2019/088573 2019-05-27
PCT/CN2020/092351 WO2020238900A1 (en) 2019-05-27 2020-05-26 Dna-dependent protein kinase inhibitor

Publications (1)

Publication Number Publication Date
CN113924305A true CN113924305A (zh) 2022-01-11

Family

ID=73551904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080039438.4A Pending CN113924305A (zh) 2019-05-27 2020-05-26 Dna依赖性蛋白激酶抑制剂

Country Status (11)

Country Link
US (1) US20220242884A1 (https=)
EP (1) EP3976624A4 (https=)
JP (1) JP7696834B2 (https=)
CN (1) CN113924305A (https=)
AR (1) AR119018A1 (https=)
AU (1) AU2020281332B2 (https=)
BR (1) BR112021023824A8 (https=)
CA (1) CA3137598A1 (https=)
MX (1) MX2021014455A (https=)
TW (1) TWI899080B (https=)
WO (1) WO2020238900A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322209A (zh) * 2022-07-19 2022-11-11 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN116239610A (zh) * 2023-02-23 2023-06-09 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213460A1 (zh) * 2020-04-23 2021-10-28 山东轩竹医药科技有限公司 三并环类激酶抑制剂
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN116669741B (zh) * 2021-01-05 2025-07-22 山东轩竹医药科技有限公司 多环类激酶抑制剂
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN116023393B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023394B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
CN101594871A (zh) * 2006-05-26 2009-12-02 诺瓦提斯公司 吡咯并嘧啶化合物及其用途
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012022681A2 (en) * 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
CN102666545A (zh) * 2009-10-20 2012-09-12 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
CN103180322A (zh) * 2010-04-30 2013-06-26 塞尔佐姆有限公司 作为jak抑制剂的吡唑化合物
CN103874699A (zh) * 2011-09-20 2014-06-18 赛尔佐姆有限公司 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
CN104640852A (zh) * 2012-04-24 2015-05-20 沃泰克斯药物股份有限公司 Dna-pk抑制剂
CN105246883A (zh) * 2013-03-12 2016-01-13 沃泰克斯药物股份有限公司 Dna-pk抑制剂
WO2018114999A1 (en) * 2016-12-20 2018-06-28 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
CN110885331A (zh) * 2018-09-11 2020-03-17 中国药科大学 一种新颖的6-氨基-1H-吡唑并[3，4-d]嘧啶类JAK激酶抑制剂的制备与应用
CN111433208A (zh) * 2017-12-05 2020-07-17 奥斯考泰克公司 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
WO2015115673A1 (en) 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
CN101594871A (zh) * 2006-05-26 2009-12-02 诺瓦提斯公司 吡咯并嘧啶化合物及其用途
CN102666545A (zh) * 2009-10-20 2012-09-12 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
CN103180322A (zh) * 2010-04-30 2013-06-26 塞尔佐姆有限公司 作为jak抑制剂的吡唑化合物
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012022681A2 (en) * 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
CN103874699A (zh) * 2011-09-20 2014-06-18 赛尔佐姆有限公司 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
CN104640852A (zh) * 2012-04-24 2015-05-20 沃泰克斯药物股份有限公司 Dna-pk抑制剂
CN105246883A (zh) * 2013-03-12 2016-01-13 沃泰克斯药物股份有限公司 Dna-pk抑制剂
WO2018114999A1 (en) * 2016-12-20 2018-06-28 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
CN111433208A (zh) * 2017-12-05 2020-07-17 奥斯考泰克公司 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物
CN110885331A (zh) * 2018-09-11 2020-03-17 中国药科大学 一种新颖的6-氨基-1H-吡唑并[3，4-d]嘧啶类JAK激酶抑制剂的制备与应用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322209A (zh) * 2022-07-19 2022-11-11 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN115322209B (zh) * 2022-07-19 2023-06-20 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN116239610A (zh) * 2023-02-23 2023-06-09 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用
CN116239610B (zh) * 2023-02-23 2024-01-16 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
JP2022534261A (ja) 2022-07-28
EP3976624A1 (en) 2022-04-06
TW202110849A (zh) 2021-03-16
TWI899080B (zh) 2025-10-01
BR112021023824A8 (pt) 2023-02-28
JP7696834B2 (ja) 2025-06-23
AR119018A1 (es) 2021-11-17
WO2020238900A1 (en) 2020-12-03
US20220242884A1 (en) 2022-08-04
AU2020281332B2 (en) 2026-04-02
MX2021014455A (es) 2022-01-06
AU2020281332A8 (en) 2021-11-18
CA3137598A1 (en) 2020-12-03
BR112021023824A2 (pt) 2022-01-04
KR20220027062A (ko) 2022-03-07
EP3976624A4 (en) 2023-06-14
AU2020281332A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
CN113924305A (zh) Dna依赖性蛋白激酶抑制剂
JP6712344B2 (ja) Ｂｅｔタンパク質阻害剤としての三環式複素環
KR102430144B1 (ko) BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
US11203594B2 (en) Anti-proliferative agents for treating PAH
WO2015006193A1 (en) Tricyclic heterocycles as bet protein inhibitors
US20240300936A1 (en) Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
RU2835434C2 (ru) Ингибитор ДНК-зависимой протеинкиназы
KR102961371B1 (ko) Dna-의존적 단백질 키나제 억제제
HK40060710A (en) Dna-dependent protein kinase inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060710

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20221220

Address after: 199 Liangjing Road, Zhangjiang hi tech park, Pudong New Area, Shanghai 201203

Applicant after: Dizhe (Jiangsu) Pharmaceutical Co.,Ltd.

Applicant after: Dizhe (Shanghai) Pharmaceutical Co.,Ltd.

Address before: 199 Liangjing Road, Zhangjiang hi tech park, Pudong New Area, Shanghai 201203

Applicant before: Dizhe (Jiangsu) Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right